Literature DB >> 6948882

Recurrent unilateral lung disease.

C Carlon, L Teba, B Maloney, S Parker.   

Abstract

A 25-year-old patient, with multiple pulmonary metastases from osteogenic sarcoma who two years ago developed respiratory failure with unilateral left lung involvement and was successfully treated with independent lung ventilation, was readmitted to an ICU with recurrent unilateral lung disease. Conventional therapy failed to reverse the respiratory failure; independent ventilation temporarily improved the patient's oxygenation. At autopsy, different involvement of the two lungs by the tumor was evident so that blood flow of the right lung and lymphatic flow of the left lung were impaired. When respiratory failure unresponsive to conventional therapy develops, anatomical abnormalities should be considered.

Entities:  

Mesh:

Year:  1981        PMID: 6948882     DOI: 10.1007/bf01709730

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  5 in total

1.  Adverse effect of positive end-expiratory pressure on pulmonary perfusion and arterial oxygenation.

Authors:  D J Kanarek; D C Shannon
Journal:  Am Rev Respir Dis       Date:  1975-09

Review 2.  Pulmonary physiologic studies of the perioperative period.

Authors:  R M Peters
Journal:  Chest       Date:  1979-11       Impact factor: 9.410

3.  Criteria for selective positive end-expiratory pressure and independent synchronized ventilation of each lung.

Authors:  G C Carlon; C Ray; R Klein; P L Goldiner; S Miodownik
Journal:  Chest       Date:  1978-11       Impact factor: 9.410

4.  Differential lung ventilation with PEEP in the treatment of unilateral pneumonia.

Authors:  D J Powner; B Eross; A Grenvik
Journal:  Crit Care Med       Date:  1977 Jul-Aug       Impact factor: 7.598

5.  Acute life-threatening ventilation-perfusion inequality: an indication for independent lung ventilation.

Authors:  G C Carlon; R Kahn; W S Howland; R Baron; J Ramaker
Journal:  Crit Care Med       Date:  1978 Nov-Dec       Impact factor: 7.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.